Bio-Rad Laboratories, Inc. BIO posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year...
Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell.The company posted adjusted earnings per share (EPS) of $3.11 in the last reported...
The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up by +0.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.79%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.07%. Stocks...
Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business...
/Bio-Rad%20Laboratories%20Inc_%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Despite Bio-Rad Laboratories’ underperformance relative to the healthcare sector over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
The quarterly rebalancing of the S&P 500 reflects market capitalization and performance shifts, highlighting growth and challenges in multiple sectors.
History says Palantir stock could soar after its inclusion in the S&P 500.
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. Stocks on Monday posted...